176 related articles for article (PubMed ID: 12741443)
41. Warfarin skin necrosis associated with protein S deficiency and a mutation in the methylenetetrahydrofolate reductase gene.
Byrne JS; Abdul Razak AR; Patchett S; Murphy GM
Clin Exp Dermatol; 2004 Jan; 29(1):35-6. PubMed ID: 14723717
[TBL] [Abstract][Full Text] [Related]
42. Severe hemorrhagic corpus luteum complicating anticoagulation in antiphospholipid syndrome.
Yamakami LY; de Araujo DB; Silva CA; Baracat EC; de Carvalho JF
Lupus; 2011 Apr; 20(5):523-6. PubMed ID: 21138983
[TBL] [Abstract][Full Text] [Related]
43. Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm.
Nauseef JT; Lim HI; DeSancho MT
J Thromb Thrombolysis; 2021 Aug; 52(2):597-600. PubMed ID: 33222114
[TBL] [Abstract][Full Text] [Related]
44. Antiphospholipid Syndrome with Antiβ2glicoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome.
Przepiera-Będzak H; Brzosko M
Acta Dermatovenerol Croat; 2016 Dec; 24(4):305-306. PubMed ID: 28128085
[TBL] [Abstract][Full Text] [Related]
45. Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).
Woller SC; Stevens SM; Kaplan DA; Branch DW; Aston VT; Wilson EL; Gallo HM; Johnson EG; Rondina MT; Lloyd JF; Evans RS; Elliott CG
Clin Appl Thromb Hemost; 2016 Apr; 22(3):239-47. PubMed ID: 26566669
[TBL] [Abstract][Full Text] [Related]
46. Bridging therapy in antiphospholipid syndrome and antiphospholipid antibodies carriers: case series and review of the literature.
Raso S; Sciascia S; Kuzenko A; Castagno I; Marozio L; Bertero MT
Autoimmun Rev; 2015 Jan; 14(1):36-42. PubMed ID: 25242343
[TBL] [Abstract][Full Text] [Related]
47. Late onset warfarin-induced skin necrosis.
Xin C; Hu D; Li M
G Ital Dermatol Venereol; 2019 Apr; 154(2):205-208. PubMed ID: 25410444
[TBL] [Abstract][Full Text] [Related]
48. Intravenous warfarin and heparin-induced thrombocytopenia: making the diagnosis, management, modern monitoring, and multidisciplinary care.
Burger CF; Schlesinger JJ
Ann Pharmacother; 2014 Feb; 48(2):286-91. PubMed ID: 24259642
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
[TBL] [Abstract][Full Text] [Related]
50. Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
Balaban M; Stanrić V; Rincić G; Ledinsky M; Grbac L; Stancić N; Tomasić H
Acta Clin Croat; 2010 Dec; 49(4):469-77. PubMed ID: 21830460
[TBL] [Abstract][Full Text] [Related]
51. The lesser known side-effect of warfarin: warfarin-induced venous limb gangrene.
Sheng GH; Aronowitz P
Mayo Clin Proc; 2014 May; 89(5):e47. PubMed ID: 24797650
[No Abstract] [Full Text] [Related]
52. Successful use of fondaparinux in a child with heparin-induced thrombocytopenia.
Tokgoz H; Caliskan U; Demir M
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):769-71. PubMed ID: 22964766
[TBL] [Abstract][Full Text] [Related]
53. Pathophysiology and treatment of deep-vein thrombosis and pulmonary embolism.
Carter BL; Jones ME; Waickman LA
Clin Pharm; 1985; 4(3):279-96. PubMed ID: 3891200
[TBL] [Abstract][Full Text] [Related]
54. Severe antiphospholipid syndrome and cardiac surgery: Perioperative management.
Mishra PK; Khazi FM; Yiu P; Billing JS
Asian Cardiovasc Thorac Ann; 2016 Jun; 24(5):473-6. PubMed ID: 25829458
[TBL] [Abstract][Full Text] [Related]
55. Venous thrombosis in the antiphospholipid syndrome.
Farmer-Boatwright MK; Roubey RA
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):321-5. PubMed ID: 19228605
[TBL] [Abstract][Full Text] [Related]
56. Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
Baquero-Salamanca M; Téllez-Arévalo AM; Calderon-Ospina C
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25858939
[TBL] [Abstract][Full Text] [Related]
57. Warfarin induced skin necrosis.
Chan YC; Valenti D; Mansfield AO; Stansby G
Br J Surg; 2000 Mar; 87(3):266-72. PubMed ID: 10718793
[TBL] [Abstract][Full Text] [Related]
58. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment.
Sallah S; Thomas DP; Roberts HR
Thromb Haemost; 1997 Aug; 78(2):785-90. PubMed ID: 9268171
[No Abstract] [Full Text] [Related]
59. Warfarin and royal jelly interaction.
Lee NJ; Fermo JD
Pharmacotherapy; 2006 Apr; 26(4):583-6. PubMed ID: 16553520
[TBL] [Abstract][Full Text] [Related]
60. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
